1. Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI (2013) Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 14(7):663–670
2. ANVISA, Agência Nacional de Vigilância Sanitária (2019) Resolução-re nº 2.282, de 16 de agosto de 2019. Diário Oficial da União.
http://www.in.gov.br/web/dou/-/resolucao-re-n-2.282-de-16-de-agosto-de-2019-211284950
. Accessed 31 Jan 2020
3. Apollonio G, Raimondi A, Verzoni E, Claps M, Sepe P, Pagani F, Ratta R, Montorsi F, De Braud FGM, Procopio G (2019) The role of metastasectomy in advanced renal cell carcinoma. Expert Rev Anticancer Ther 19(7):603–611
4. Armstrong AJ, Broderick S, Eisen T, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, Lusk CM, Oberg S, Halabi S, George DJ (2015) Final clinical results of a randomized phase II international trial of everolimus vs sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN). J Clin Oncol 2015:33
5. Atkins MB, McDermott DF, Powles T, Motzer RJ, Rini BI, Fong L, Joseph RW, Pal SK, Sznol M, Hainsworth JD, Stadler WM, Hutson TE, Ravaud A, Bracarda S, Suarez C, Choueiri TK, Qiu J, Huseni MA, Schiff C, Escudier BJ (2017) IMmotion150: a phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). J Clin Oncol 2017:35